Moors Cabot buys $13,419,097 stake in Johnson & Johnson (JNJ)

Johnson & Johnson (JNJ) : Moors Cabot scooped up 4,717 additional shares in Johnson & Johnson during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Nov 14, 2016. The investment management firm now holds a total of 113,270 shares of Johnson & Johnson which is valued at $13,419,097.Johnson & Johnson makes up approximately 2.28% of Moors Cabot’s portfolio.

Other Hedge Funds, Including , Oppenheimerfunds reduced its stake in JNJ by selling 1,143,929 shares or 22.94% in the most recent quarter. The Hedge Fund company now holds 3,841,787 shares of JNJ which is valued at $447,952,364. Johnson & Johnson makes up approx 0.57% of Oppenheimerfunds’s portfolio.Fagan Associates reduced its stake in JNJ by selling 134 shares or 0.69% in the most recent quarter. The Hedge Fund company now holds 19,254 shares of JNJ which is valued at $2,246,172. Johnson & Johnson makes up approx 1.40% of Fagan Associates’s portfolio.Visionary Asset Management boosted its stake in JNJ in the latest quarter, The investment management firm added 710 additional shares and now holds a total of 27,163 shares of Johnson & Johnson which is valued at $3,126,733. Johnson & Johnson makes up approx 1.13% of Visionary Asset Management’s portfolio.Hourglass Capital reduced its stake in JNJ by selling 60 shares or 0.21% in the most recent quarter. The Hedge Fund company now holds 29,153 shares of JNJ which is valued at $3,353,470. Johnson & Johnson makes up approx 0.87% of Hourglass Capital’s portfolio.Cape Cod Five Cents Savings Bank reduced its stake in JNJ by selling 3,107 shares or 2.52% in the most recent quarter. The Hedge Fund company now holds 119,995 shares of JNJ which is valued at $13,746,627. Johnson & Johnson makes up approx 2.56% of Cape Cod Five Cents Savings Bank’s portfolio.

Johnson & Johnson closed down -0.41 points or -0.35% at $115.36 with 77,17,773 shares getting traded on Monday. Post opening the session at $115.79, the shares hit an intraday low of $114.81 and an intraday high of $115.92 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

On the company’s financial health, Johnson & Johnson reported $1.68 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Oct 18, 2016. Analyst had a consensus of $1.66. The company had revenue of $17820.00 million for the quarter, compared to analysts expectations of $17744.90 million. The company’s revenue was up 4.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.49 EPS.

Johnson & Johnson is a holding company. The Company is engaged in the research and development manufacture and sale of a range of products in the health care field. The Company has more than 265 operating companies conducting business around the world. The Company’s primary focus is products related to human health and well-being. The Company is organized into three business segments: Consumer Pharmaceutical and Medical Devices. The Company’s subsidiaries operate 134 manufacturing facilities occupying approximately 21.5 million square feet of floor space. The Company’s research facilities are located in the United States Belgium Brazil Canada China France Germany India Israel Japan the Netherlands Singapore Switzerland and the United Kingdom.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Johnson & Johnson - Is it time to Sell?

Top Brokerage Firms are advising their investors on Johnson & Johnson. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.